Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease ...
...Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a leading cause of morbidity and mortality, and health disparities have been shown to influence disease burden....
https://pubmed.ncbi.nlm.nih.gov/39560808/
Scholars@Duke publication: Disparities in Metabolic Dysfunction ...
...Miller, K. C., Geyer, B., Alexopoulos, A.-S., Moylan, C. A., & Pagidipati, N. (2025). Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence, Diagnosis, Treatment, and Outcomes: A Narrative Review. Dig Dis Sci, 70 (1), 154?167. https://doi.org/10.1007/s10620-024-08722-0...
https://scholars.duke.edu/publication/1655358
Serial Liver Stiffness Measurement and Fibrosis-4 Scores in Metabolic ...
...Changes in FIB4 correlated with changes in LSM (R = 0.16, p = 0.016). Independent predictors of incident SF included comorbid diabetes mellitus (OR 2.43, 95% CI 1.04-6.56), obesity (OR 3.88, 95% CI 1.63-9.25), and baseline ALT ? 30 (OR 8.55, 95% CI 1.10-66.29)....
https://www.semanticscholar.org/paper/Serial-Liver-Stiffness-Measurement-and-Fibrosis-4-Goyal-Song/b02d6511444b063d84f62e611d18ac30328b7b76
Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease ...
...Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a leading cause of morbidity and mortality, and health disparities have been shown to influence disease burden....
https://link.springer.com/article/10.1007/s10620-024-08722-0
Disparities in Metabolic Dysfunction-Associated Steatotic ... - Springer
...The risk of disease was quanti?ed in a 2018 systematic review and meta-analysis of 34 studies, that found, compared to non- Hispanic White patients, a relative risk of MASLD of 1.36 (95% CI=1.08?1.73) for Hispanic patients and 0.68 (95% CI=0.54?0.84) for non-Hispanic Black patients [6]....
https://link.springer.com/content/pdf/10.1007/s10620-024-08722-0.pdf
Effect of Concurrent Metabolic Dysfunction-Associated ... - PubMed
...We found no evidence of an association between concurrent MASLD and fibrosis progression amongst CHB patients without baseline advanced liver disease. APRI and FIB-4 may have reduced accuracy in MASLD patients....
https://pubmed.ncbi.nlm.nih.gov/38376788/
Review of Current and Upcoming Second-Line Treatments for Primary ...
...Background Treatment for primary biliary cholangitis (PBC) was defined by its singular relationship with ursodeoxycholic acid (UDCA) for decades. However, nearly 40% of patients fail to achieve......
https://www.researchgate.net/publication/386341127_Review_of_Current_and_Upcoming_Second-Line_Treatments_for_Primary_Biliary_Cholangitis
Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease ...
...Full text links Read article at publisher's site: https://doi.org/10.1007/s10620-024-08722-0...
https://europepmc.org/article/med/39560808
Review of Current and Upcoming Second-Line Treatments for Primary ...
...Aims: The aim of our review was to assess the efficacy and safety of second-line therapies for PBC from phase three trials. Methods: We conducted a systematic review of PubMed, Medline, and ClinicalTrials.gov for published phase three trial data of second-line PBC therapies....
https://pubmed.ncbi.nlm.nih.gov/39621183/
Effectiveness of Exercise Interventions on Body Composition, Exercise ...
...Aamann et al. published a systematic review and meta-analysis on exercise intervention in patients with liver cirrhosis in 2018, with the primary purpose of determining whether exercise intervention reduces mortality and serious adverse events [27]....
https://link.springer.com/article/10.1007/s10620-024-08447-0